Stock Market Reviews

ACB (Aurora Cannabis Inc.) News

Get the latest news, insights, and market updates on ACB (Aurora Cannabis Inc.). Explore the news page 6 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Aurora Cannabis (TSX:ACB) Trades at 1x Sales with Revenue Forecast to Grow 6.5% Annually
  Aurora Cannabis (TSX:ACB) remains unprofitable, but has managed to reduce its losses at an impressive rate of 61.2% per year over the last five years. Looking ahead, analysts expect the company’s revenue to grow 6.5% per year, outpacing the Canadian market’s average forecast of 5.1%. With no major risks flagged in the current data and shares trading below an estimated fair value of CA$23.27, investors are likely watching the rapid loss reduction and better-than-market revenue outlook closely...
  Nov 6, 2025 - $ACB
• Aurora Cannabis Swings to Q2 Loss Despite Revenue Beat and Higher Medical Cannabis Sales
  Aurora Cannabis (NASDAQ: ACB, TSX: ACB), a Canada-based global medical cannabis company on Wednesday
  Nov 5, 2025 - $ACB
• Aurora Cannabis Inc. (ACB) Tops Q2 Earnings and Revenue Estimates
  Aurora Cannabis (ACB) delivered earnings and revenue surprises of +200.00% and +2.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $ACB
• Aurora Cannabis Announces Fiscal 2026 Second Quarter Results
  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.
  Nov 5, 2025 - $ACB
• How to Play Aurora Cannabis Stock Amid Renewed Legalization Hopes?
  Aurora Cannabis gains 21% as its medical segment fuels revenue and margin growth, even as recreational sales drag.
  Oct 22, 2025 - $ACB
• Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call
  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2026 before the opening of markets that same day.
  Oct 22, 2025 - $ACB
• Tilray Brands (TLRY) Climbs 8% Ahead of Cannabis, CBD Policy Decision
  We recently published 10 Hot Stocks Sparking Buying Frenzy. Tilray Brands Inc. (NASDAQ:TLRY) is one of the best performers on Tuesday. Tilray Brands Inc. (NASDAQ:TLRY) grew its share prices by 8.23 percent on Tuesday to finish at $1.71 apiece as investors repositioned portfolios ahead of an expected decision from President Donald Trump on the legalization […]
  Oct 8, 2025 - $ACB
• Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?
  Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Oct 8, 2025 - $ACB
• Cannabis stocks are on a roll: Here's how to play the surge
  Cannabis stocks are in focus after President Trump said CBD could "revolutionize senior healthcare" in a Truth Social post. The comment sent bullish signals through the cannabis space, coming months after reports that the president was considering reclassifying weed. AdvisorShares Pure US Cannabis ETF (MSOS) portfolio manager Dan Ahrens joins Market Catalysts to take a closer look at the cannabis space and how to invest in it. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
  Oct 4, 2025 - $ACB
• Aurora Cannabis (TSX:ACB): Exploring Valuation After U.S. Signals Possible Shift in CBD and Marijuana Policy
  Aurora Cannabis (TSX:ACB) shares jumped following President Donald Trump's endorsement of cannabidiol, or CBD, as an alternative in senior healthcare, along with growing speculation about changes to U.S. federal marijuana regulations. See our latest analysis for Aurora Cannabis. Momentum has clearly picked up for Aurora Cannabis, as the company’s shares surged more than 28% after President Trump’s endorsement of CBD and fresh speculation around federal marijuana reform. While the one-year...
  Oct 3, 2025 - $ACB